Background: Tenofovir with full-dose didanosine has been associated with paradoxical CD41 T cell decrease despite virological suppression. We investigated whether tenofovir plus didanosine at a weight-adjusted dosage could be responsible for such an effect, and factors associated with CD41 T cell count evolution under this combination.
Introduction
The use of tenofovir disoproxil fumarate in combination with didanosine has been considered an attractive option as a possible nucleoside reverse transcriptase inhibitor (NRTI) backbone of highly active antiretroviral therapy (HAART) because of its convenient posology (two pills once daily, regardless of food intake). Nonetheless, many studies have reported unexpected CD4þ T cell count decrease in patients treated with didanosine at unadjusted dosages in combination with tenofovir, 1 -4 and this was correlated with pharmacokinetic interactions, possibly resulting in a dose-related didanosine toxicity for lymphocytes. 5 The same phenomenon could be responsible for the compromised immunological recovery reported in experienced patients treated with enfuvirtide in combination with tenofovir and fulldose didanosine. 6 An analysis conducted by Karrer et al. 7 demonstrated that immune depletion was less likely to occur if the didanosine dosage was adjusted to ,4.1 mg/kg/day, which is close to the currently recommended dosage when didanosine is co-administered with tenofovir (i.e. 250 mg/day in patients weighing .60 kg). However, neither this analysis nor other available studies have fully accounted for the possible impact of HIV replication on CD4þ T lymphocytes, as they included patients either naive or experienced to antiretroviral drugs, with either detectable or undetectable HIV plasma viral load at baseline or during follow-up. Moreover, paradoxical CD4þ T cell count decrease was also evident in a minority of patients treated with weight-adjusted didanosine dosages, suggesting that variables other than per-kilo dosage may be responsible for this side effect.
Tenofovir plus didanosine is not considered a standard backbone combination because of high risk of virological failure in naive patients. 8 -11 Notwithstanding, this combination has been used in several patients when other options were precluded because of previous treatment failure or intolerance to alternative drugs. Therefore, the aim of our study was to investigate whether the introduction of tenofovir plus didanosine in a weight-adjusted dosage in fully virologically suppressed patients was associated with a paradoxical decrease in the CD4þ T cell count or with a reduction in their trend of increase. Moreover, we explored what factors may influence CD4þ T cell count evolution in these patients.
Materials and methods

Patients
Patients were selected from the Italian MASTER cohort, which is a prospective longitudinal multicentre cohort composed of the general HIV patient population in referral centres throughout Italy. The distinguishing characteristic of this cohort is that data are collected by a common electronic database (Health & Notes version 3.5, Healthware S.p.A., Naples, Italy) in use in 11 Italian centres for clinical purposes since 1999. The electronic database is implemented to manage everyday activity of the outpatient HIV clinics in each centre. The resulting cohort is, therefore, an open cohort in which non-pre-selected patients are continuously enrolled. Demographics, medication and disease history are recorded at enrolment and updated on a 3 monthly basis. In order to increase the sample size, data from the MASTER cohort were merged with those from the Hospital Carlos III in Madrid (Spain), also recorded at similar intervals.
All HIV-1-positive patients who switched from an effective HAART regimen to a new regimen including tenofovir in combination with didanosine at a weight-adjusted dosage were eligible for the study, provided that HIV plasma viral loads were persistently undetectable (i.e. ,50 copies/mL) during the previous 6 months. Patients were excluded from the analysis if they had previously experienced the tenofovir and didanosine combination, although they were still eligible if one or both drugs had been taken separately. Treatment intensification by the mere addition of either tenofovir or didanosine to the ongoing HAART was not allowed. Other exclusion criteria were the use of interferon-based treatment or bone marrow stimulating factors during the observation or lack of a weight determination within 180 days before or after switching. Right censoring of follow-up was applied when any change in the regimen prescribed at switching occurred, at the time of the first detectable HIV plasma viral load or when any clinical event (i.e. death or HIV-related diseases) occurred, whichever was the first to occur.
Statistical analysis
Two study outcomes were considered: absolute CD4þ T cell count and CD4þ T cell percentage value over total lymphocytes. As longitudinal data were available, linear mixed models were used to derive time-adjusted absolute CD4þ T cell count or percentage changes over time (i.e. slopes). MIXED procedure in SAS was used by fitting values of CD4þ T cell count or percentages from all study time points as dependent variables. Independent variables included the fixed effects of intervention, study visit time points grouped into 3 month category and 1 year category and intervention by time interaction. An unstructured co-variance matrix was used to model the within-patient errors.
Estimates of CD4þ T cell slopes from switching were obtained by time interaction. Trends over time are presented as point estimates with 95% confidence interval (95% CI). Further multivariable analysis is presented adjusted for other co-variables assumed to have a potential confounding or residual effect on trends in CD4þ T cell counts over time.
The following co-variables were considered: age, gender, nationality (European versus others), weight, risk factor for HIV acquisition [intravenous drug user (IVDU) versus others], clinical stage of HIV infection (CDC '93 class C versus others), serum reactivity for hepatitis C virus (HCV) antibodies (Ab), CD4þ T cell count at nadir (i.e. the lowest value ever recorded), CD4þ T cell count at the time of switching, creatinine clearance at the time of switching (calculated according to the Crockroft -Gault formula with actual body weight), per-kilo didanosine dosage (mg/kg), type of third drug associated with tenofovir plus didanosine [i.e. other NRTI, non-NRTI (NNRTI) or single or boosted protease inhibitor], previous exposure to tenofovir, previous exposure to didanosine, cumulative previous exposure to didanosine (months), number of drugs experienced (ritonavir and saquinavir used as booster were not considered), number of treatment lines experienced and duration of HIV plasma viral load undetectability prior to switching (months). Owing to co-correlation between explanatory variables, several multivariable models were generated and the model that was considered most clinically and statistically significant is presented.
A supplementary analysis (simple-segmented linear regression) of change in the CD4þ T cell count slope before and after tenofovir plus didanosine was conducted using Stata Software. The change in the annual slope of CD4þ T cell count was estimated using the 1 year CD4þ T cell count slope preceding the switch to predict CD4þ T cell count levels at 1 year after tenofovir plus didanosine introduction and computing the difference between observed and predicted CD4þ T cell count values. Possible abrupt variation in the outcome, e.g. a jump or drop in CD4þ T cell count levels after tenofovir plus didanosine, was also investigated by comparing the value of the series at the beginning of the time interval (i.e. the y-intercept for the first segment) and the value immediately following at which the successive segment joins.
All statistical analyses were performed using SAS V8 and Stata 8.0 and all P values presented are two-tailed.
Results
Patients
One thousand, one hundred and seventy-five patients in the MASTER cohort and 463 patients in the Hospital Carlos III HIV cohort were prescribed tenofovir plus didanosine combinations. Among them, 1100 and 378 were experienced to antiretroviral drugs in the two cohorts, respectively; 230 and 157 were switched to this combination with undetectable HIV plasma viral load, of whom 99 and 18 had HIV plasma viral load persistently undetectable for at least 6 months before switching. Of these patients, six were excluded because they had undergone interferon-based treatment during the follow-up and three due to the absence of weight recorded within the stated time frame. The characteristics of the remaining 108 patients included in the study are summarized in Table 1 . Median CD4þ T cell count at the time of switching was high (439 cells/mm 3 ) and the tenofovir plus didanosine backbone was prescribed mainly with an NNRTI. The median duration of follow-up prior to the switch was 14 [interquartile range (IQR) 9 -24] months, whereas patients were followed for a median of 12 (IQR 6-19) months thereafter. Median number of CD4þ T cell count determinations per patient before and after the switch was 5 (IQR 3 -8) and 4 (IQR 3 -7), respectively. No significant differences were found comparing the MASTER patients with those from Hospital Carlos III.
CD4þ T cell evolution
As shown in Figure 1(a) , the introduction of tenofovir plus didanosine was not associated with any paradoxical decline in the CD4þ T cell count using the linear mixed model. In fact, the model estimated a significant CD4þ gain after 12 (30 cells/ mm 3 ; P ¼ 0.02) and 24 months (45 cells/mm 3 ; P ¼ 0.003) from switching. Similar results were obtained when the CD4þ percentage value over total lymphocytes was considered as the outcome measure (Figure 1b) . When compared with pre-switch levels, the CD4þ percentage was significantly higher at 12 and 24 months after switching (0.9 percentage-point; P ¼ 0.02 and 1.6 percentage-point; P ¼ 0.001, respectively).
Slope of CD4þ T cells
CD4þ T cell count slope did not change significantly after prescription of tenofovir and didanosine when the linear mixed model was used. The annual time-weighted CD4þ T cell count slope before switching was þ14 cells/mm 3 (95% CI 27 to 35) from month 224 to month 212 and þ12 cells/mm 3 (95% CI 214 to 38) from month 212 to the time of switching. After the introduction of tenofovir plus didanosine, the CD4þ T cell count slope was þ30 (95% CI þ5 to þ55) from switching to month þ12 and þ15 (95% CI 28 to þ39) from month þ12 to month þ24. Likewise, the slope of percentage CD4þ T cell count among total lymphocytes did not vary significantly from the introduction of tenofovir plus didanosine. Before switching, the time-weighted percentage CD4þ T cell slope was þ1.3 percentage-points (95% CI 0.7-1.9) from month 224 to month 212 and þ0.4 percentage-points (95% CI 20.4 to 1.1) from month 212 to time 0. Following the switch, the slope was þ0.9 percentage-points (95% CI þ0.1 to þ1.6) and þ0.7 percentagepoints (95% CI 0 to þ1.4) from introduction of tenofovir plus didanosine to month þ12 and from month þ12 to month þ24, respectively. We further investigated these trends using the segmented regression analysis method. This also demonstrated no significant change in the slope of the segment after the switch to the tenofovir plus didanosine-containing regimens when compared with the segment prior to the intervention (slope change: þ24 cells/mm 3 ; 95% CI 210 to þ58). Furthermore, no significant level change (i.e. abrupt variation in CD4þ T cell count immediately after intervention) was detected (level change: þ11 cells/mm 3 ; 95% CI 27 to þ28).
Predictors of CD4þ T cell evolution Table 2 shows a multivariable MIXED model showing factors adjusted for each other. Older age (years) (P ¼ 0.02), lower nadir CD4þ T cell count (P , 0.001) and positive HCV-Ab (P ¼ 0.03) were significantly associated with decreasing CD4þ T cell count slope across the follow-up. Moreover, lower creatinine clearance was significantly correlated with lower CD4þ T cell count slope using univariate analysis, but could not be input in the multivariable analysis because of a significant co-correlation with nadir CD4þ T cell count. Nonetheless, its independent predictive value was demonstrated in a model without nadir CD4þ T cell count (2.2 cells/mm 3 per mL/min increase; 95% CI 0.4-4; P ¼ 0.02).
The change in point estimates produced by these factors in the adjusted model was very slight, however, thus indicating little or no confounding effect (Figure 1a) . Similarly, no significant changes occurred in the CD4þ T cell percentage model (Figure 1b) when it was adjusted for nadir CD4þ T cell count, the only significant independent predictor of percentage CD4þ T cell slope (0.04; 95% CI 0.03-0.05; P , 0.001). The adjusted segmented regression models also showed similar findings. This indicated that CD4þ T cell count slope or CD4þ T cell count level did not change significantly after switching to tenofovir plus didanosine, even adjusting for possible explanatory variables.
Discussion
In our cohort, the use of tenofovir in combination with didanosine was not associated with a significant change in the trend of CD4þ T cell count which was ongoing before switching to this combination. In other terms, we did not observe a significant drop in CD4þ T cell count as a result of tenofovir plus didanosine introduction, although a great interindividual variability was present. Different hypotheses may be formulated to explain why our findings partially differed from those of the studies that demonstrated the immune-toxicity of this combination. 1 -4,6,7 First, in our cohort, didanosine was never used at 400 mg/day, a dosage that is no longer recommended when didanosine is administered in combination with tenofovir. In other studies, a proportion varying from 30% to 100% of patients received a didanosine dose higher than that now recommended. Therefore, our cohort is more likely to represent current clinical practice and our results suggest that immune recovery is not impaired when didanosine is prescribed at weight-adjusted dosages. This is consistent with previous observations of partial CD4þ recovery after didanosine dosage reduction 1, 3 and with the identification of a threshold for didanosine dosage, below which immune-toxicity is unlikely to occur. 7 Secondly, only patients who switched to tenofovir and didanosine with full virological suppression were studied. In a previous study, a greater decline in HIV plasma viral load was associated with a steeper CD4þ T cell increase and this could have influenced the results. 7 Moreover, in some studies, HIV replication was more frequently detected among subjects taking tenofovir plus didanosine, 4 thus hampering CD4þ T cell gain in this group of patients. In our study, a possible effect resulting from different levels of HIV replication was removed by considering patients provided that their HIV plasma viral load remained ,50 copies/mL.
Thirdly, even though switching to tenofovir plus didanosinecontaining treatment was not associated with a paradoxical CD4þ T cell loss, other factors, which were not invariably taken into account in previous studies, were associated with a reduced immune recovery, despite full virological suppression induced by HAART. In particular, patients with advanced HIV disease, as proved by a low nadir CD4þ T cell count, had smaller CD4þ T cell gains. The reduced immune recovery observed in some patients was therefore more likely to be due to the degree of the previous immune damage, rather than to the introduction of a particular drug combination, as already suggested by others. 12 The association between higher per-kilo didanosine dosage and reduced CD4þ T cell slope was present at univariate analysis, but disappeared after adjustment for nadir CD4þ T cell count. This was probably due to the fact that weight of patients with low nadir CD4þ T cell count was lower than that of the others (mean weight 71.4 and 65.1 kg among patients with nadir or ,200 cells/mm 3 , respectively; t-test P ¼ 0.015). Older age, HCV co-infection and renal function impairment were also independently associated with blunted CD4þ T cell recovery. Some hypotheses can be raised to explain these findings. Ageing is known to compromise immunological gain after HAART, 13 and this phenomenon is probably related to a decreased proliferation of lymphocytes, 14 as well as to their increased susceptibility to apoptosis. 15, 16 Similarly, higher rates of apoptosis of naive CD4þ T cells have been demonstrated in HCV-co-infected than in HIV-monoinfected individuals. 17 The association between impaired immune reconstitution and reduced creatinine clearance may be interpreted in different ways. Renal dysfunction could be an epiphenomenon of severe immune damage, thus explaining why it was co-linear with disease stage and associated with lower CD4þ T cell gain. Renal dysfunction could be directly responsible for reduced CD4þ T cell gain because of cytokine unbalance, as suggested by a previous study. 18 In contrast, renal dysfunction could act through an indirect mechanism, increasing didanosine plasma levels and its dose-related toxicity on lymphocytes.
Our study has several limitations that should be acknowledged. First, the analysis was conducted with an as-treated approach, with observation of patients restricted to those with complete virological suppression and the censoring of the observation if the patient changed treatment. Therefore, our study was not designed to investigate virological effectiveness of this combination. This was done deliberately, because patients were heterogeneous in terms of clinical and treatment history and a carefully matched control group would have been difficult to obtain. Moreover, only a careful monitoring of patient adherence to treatment would give reliable information in this respect. However, it should be kept in mind that a higher risk of virological failure has been associated with tenofovir plus didanosine use, especially among naive patients and in combination with NNRTI. 8 -11,19 In the light of these observations, antiretroviral treatment guidelines contraindicated this backbone as part of first-line regimens.
20 Risk of virological ineffectiveness should also be taken into account when this combination is used in experienced patients.
Secondly, the small sample size and the relative shortness of the follow-up do not have the potential to detect minor or delayed variations in the CD4þ T cell slope, although patients had been followed up to a maximum of 24 months after switching.
Thirdly, long-term tolerability of tenofovir plus didanosine was not assessed in this study. Although tolerability and toxicity profiles could be improved by using weight-adjusted doses of didanosine, a possible increased risk of toxicity is still present. 21 -23 Therefore, careful surveillance is needed when tenofovir plus didanosine is used.
In conclusion, paradoxical CD4þ T cell loss was not related to the introduction of tenofovir plus didanosine (low dose) after excluding the possible influence of positive HIV plasma viral load in our series of patients. Factors explaining interindividual variability could explain blunted CD4þ T cell recoveries and/or paradoxical declines in former studies using higher doses of didanosine and/or longer follow-ups. In the meantime, our results are reassuring about the safety of this combination, as far as immune-toxicity is concerned. Therefore, we suggest that the use of tenofovir plus didanosine as backbone in experienced patients with lack of alternative options should not be avoided just because of immune-toxicity risk. 
